Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Sutro Biopharma, Inc.NASDAQ: STRO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $14.52M fell 16.5% year over year, behind the +49.9% change in trailing-twelve-month revenue. Sequentially, it rose 24.7% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of $48.04M (-53.1%) for the fiscal year ending Dec 2026, a slowdown from the +65.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.52M+24.7% QoQ
- Last fiscal yearDec 2025
- $102.48M+65.2% YoY
- LTMMar 2026
- $99.61M+49.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -16.5% | -81.2% | -64.7 pp |
| 1 year | +65.2% | -53.1% | -118.3 pp |
| 3-year CAGR | +14.8% | -27.4% | -42.2 pp |
| 5-year CAGR | -5.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 102.48M USD
- Year-over-year change
- +65.2%
- 4-year CAGR
- +13.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102.48M | +65.2% |
| FY2024 | 2024-12-31 | 62.04M | -59.6% |
| FY2023 | 2023-12-31 | 153.73M | +126.8% |
| FY2022 | 2022-12-31 | 67.77M | +9.5% |
| FY2021 | 2021-12-31 | 61.88M | — |
Revenue vs competitors
How STRO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +49.9% is the highest of 6, against a peer median of -78.3%.
- Over three fiscal years its annual growth of +14.8% compares with a peer median of +13.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $99.61M USD | +49.9% | +14.8% | |
| LTM Mar 2026 | $45.07M USD | -11.9% | +10.9% | |
| LTM Mar 2026 | $1M USD | -78.3% | +15.3% | |
| FY2025 | $64K USD | -99.8% | — | |
| LTM Mar 2026 | €29.33K EUR | -77.4% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — |
| LTM Mar 2026 | $0 USD | — | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $0 USD | — | — |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
| Peer median (excluding STRO) | — | -78.3% | +13.1% | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M |
| Gross Profit | 52.11M | 59.48M | 146.92M | 54.83M | 95.16M |
| Gross Margin | 84.2% | 87.8% | 95.6% | 88.4% | 92.9% |
| Research & Development | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M |
| Selling, General & Admin | 56M | 59.54M | 62.58M | 48.45M | 41.02M |
| Operating Expenses | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M |
| Depreciation & Amortization | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M |
| EBITDA | (97.56M) | (105.07M) | (67.92M) | (180.45M) | (145.65M) |
| EBITDA Margin | -157.7% | -155.0% | -44.2% | -290.9% | -142.1% |
| Operating Income | (98.52M) | (128.94M) | (89.28M) | (238.45M) | (104.95M) |
| Operating Margin | -159.2% | -190.3% | -58.1% | -384.3% | -102.4% |
| Interest Income | 577K | 3.46M | 14.51M | 44.43M | 9.25M |
| Interest Expense | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M |
| Other Income / Expenses | (7.01M) | 12.24M | 677K | 13.36M | (86.23M) |
| Income Before Tax | (105.54M) | (116.7M) | (88.6M) | (225.1M) | (191.18M) |
| Pre-Tax Margin | -170.6% | -172.2% | -57.6% | -362.8% | -186.5% |
| Income Tax Expense | 0 | 2.5M | 18.19M | 2.36M | (93K) |
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Net Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (Basic) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| EPS (Diluted) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| Weighted Avg Shares | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
| Weighted Avg Shares (Diluted) | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.